228 related articles for article (PubMed ID: 27171855)
21. Trends in the Use of Stereotactic Body Radiotherapy for Treatment of Prostate Cancer in the United States.
Mahase SS; D'Angelo D; Kang J; Hu JC; Barbieri CE; Nagar H
JAMA Netw Open; 2020 Feb; 3(2):e1920471. PubMed ID: 32022878
[TBL] [Abstract][Full Text] [Related]
22. ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial.
Zilli T; Scorsetti M; Zwahlen D; Franzese C; Förster R; Giaj-Levra N; Koutsouvelis N; Bertaut A; Zimmermann M; D'Agostino GR; Alongi F; Guckenberger M; Miralbell R
Radiat Oncol; 2018 Sep; 13(1):166. PubMed ID: 30180867
[TBL] [Abstract][Full Text] [Related]
23. Prostate brachytherapy: a descriptive analysis from CaPSURE.
Lee WR; Sharkey J; Cowan JE; DuChane J; Carroll PR;
Brachytherapy; 2007; 6(2):123-8. PubMed ID: 17434105
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic body radiation therapy for prostate cancer-a review.
Haque W; Butler EB; Teh BS
Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S10. PubMed ID: 28917248
[TBL] [Abstract][Full Text] [Related]
25. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
26. Increase in the use of lung stereotactic body radiotherapy without a preceding biopsy in the United States.
Rutter CE; Corso CD; Park HS; Mancini BR; Yeboa DN; Lester-Coll NH; Kim AW; Decker RH
Lung Cancer; 2014 Sep; 85(3):390-4. PubMed ID: 25001510
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer.
Anwar M; Weinberg V; Seymour Z; Hsu IJ; Roach M; Gottschalk AR
Radiat Oncol; 2016 Jan; 11():8. PubMed ID: 26792201
[TBL] [Abstract][Full Text] [Related]
28. Determinants of the combined use of external beam radiotherapy and brachytherapy for low-risk, clinically localized prostate cancer.
Quek RG; Master VA; Ward KC; Lin CC; Virgo KS; Portier KM; Lipscomb J
Cancer; 2013 Oct; 119(20):3619-28. PubMed ID: 23913478
[TBL] [Abstract][Full Text] [Related]
29. Factors Influencing Noncompletion of Radiation Therapy Among Men With Localized Prostate Cancer.
Dee EC; Muralidhar V; Arega MA; Kishan AU; Spratt DE; Dess RT; King MT; Sha ST; Santos PMG; Butler SS; Sanford NN; Nguyen PL; Mahal BA
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1279-1285. PubMed ID: 33276019
[TBL] [Abstract][Full Text] [Related]
30. The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base.
Martin JM; Handorf EA; Kutikov A; Uzzo RG; Bekelman JE; Horwitz EM; Smaldone MC
Cancer; 2014 Jul; 120(14):2114-21. PubMed ID: 24737481
[TBL] [Abstract][Full Text] [Related]
31. The use of supplemental external beam radiotherapy in men with low-risk prostate cancer undergoing brachytherapy before and after the 1999 American Brachytherapy Society Guideline statement.
Cheung AK; Chen MH; Moran BJ; Braccioforte MH; Dosoretz DE; Salenius S; Katin M; Ross R; D'Amico AV
Brachytherapy; 2010; 9(2):145-50. PubMed ID: 20346894
[TBL] [Abstract][Full Text] [Related]
32. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
33. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.
Fuller DB; Naitoh J; Lee C; Hardy S; Jin H
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1588-97. PubMed ID: 18374232
[TBL] [Abstract][Full Text] [Related]
34. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
[TBL] [Abstract][Full Text] [Related]
35. Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer.
Kishan AU; King CR
Semin Radiat Oncol; 2017 Jul; 27(3):268-278. PubMed ID: 28577834
[TBL] [Abstract][Full Text] [Related]
36. Prostate stereotactic body radiotherapy—first UK experience.
Tree AC; Ostler P; Hoskin P; Dankulchai P; Nariyangadu P; Hughes RJ; Wells E; Taylor H; Khoo VS; van As NJ
Clin Oncol (R Coll Radiol); 2014 Dec; 26(12):757-61. PubMed ID: 25193299
[TBL] [Abstract][Full Text] [Related]
37. Current use of stereotactic body radiation therapy for low and intermediate risk prostate cancer: A National Cancer Database Analysis.
Malouff TD; Stross WC; Seneviratne DS; Waddle MR; May BC; Buskirk SJ; Tzou KS
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):349-355. PubMed ID: 31780782
[TBL] [Abstract][Full Text] [Related]
38. [Stereotactic Body Radiotherapy of Prostate Cancer - Effectiveness and Toxicity].
Skácelíková E; Feltl D; Cvek J; Jelenová T; Knybel L; Tomášková H
Klin Onkol; 2017; 30(2):121-127. PubMed ID: 28397507
[TBL] [Abstract][Full Text] [Related]
39. Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base.
Amini A; Rusthoven CG; Jones BL; Armstrong H; Raben D; Kavanagh BD
Urol Oncol; 2016 Apr; 34(4):165.e1-9. PubMed ID: 26699831
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic Body Radiotherapy for Primary Prostate Cancer.
Kothari G; Loblaw A; Tree AC; van As NJ; Moghanaki D; Lo SS; Ost P; Siva S
Technol Cancer Res Treat; 2018 Jan; 17():1533033818789633. PubMed ID: 30064301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
